Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2024-03-04 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团十届二十三次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details the election of a vice chairman, committee member appointments, project approvals, guarantee plans, financing limits, and amendments to company bylaws and rules. The document is structured as a board meeting resolution announcement, not a full report or financial statement. It does not contain financial data or detailed management discussion but focuses on board decisions and governance matters. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short (2024 characters), and it is not an announcement of a report publication but a substantive announcement of board decisions.
2024-03-04 Chinese
昆药集团股份有限公司董事会议事规则
Governance Information Classification · 95% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors Meeting' and contains detailed governance rules about the board's decision-making processes, meeting procedures, voting, and responsibilities. It references the company law and company articles but does not contain financial data, audit results, or any report of financial performance. It is a governance document detailing internal rules and board structure rather than a report or announcement of financial results or corporate actions. Therefore, it fits the category of Governance Information (CGR). The document length is over 5,000 characters and is substantive, so it is not a mere announcement or regulatory filing. Hence, the classification is CGR with high confidence.
2024-03-04 Chinese
昆药集团十届二十一次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a short announcement of a supervisory board meeting resolution by Kunming Pharmaceutical Group Co., Ltd. It reports the approval of a 2024 guarantee plan proposal and states that the proposal will be submitted to the shareholders' meeting for further approval. The document is only 452 characters long and does not contain detailed financial data or a full report. It is an official announcement of a board/management decision rather than a full management report or financial statement. Therefore, it fits best under Board/Management Information (MANG).
2024-03-04 Chinese
昆药集团关于对外担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of external guarantees provided by the company to its subsidiaries. It details the guarantee amounts, the parties involved, financial data of the guaranteed company, and the board's opinions on the guarantees. The document is an announcement about financing guarantees and does not contain financial statements or detailed financial performance data. It is not a full financial report, earnings release, or management discussion. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company.
2024-02-22 Chinese
北京德恒（昆明）律师事务所关于昆药集团股份有限公司2024年第二次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion from a law firm regarding the convening, attendance, and voting procedures of a company's 2024 second extraordinary general meeting of shareholders. It details the legality and validity of the meeting and resolutions passed, including attendance and voting results. This is not a full report or financial statement but a legal opinion related to a shareholders' meeting. It does not contain financial data or management discussion but focuses on the meeting's procedural legality. Therefore, it fits best under Regulatory Filings (RNS) as a legal proceeding or compliance-related document rather than a full report or announcement of voting results.
2024-02-02 Chinese
昆药集团2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the company's 2024 second extraordinary general meeting of shareholders. It details the meeting date, attendance, voting results, and legal compliance confirmation by lawyers. There is no financial data or report content, only the official voting results and meeting procedural information. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2024-02-02 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.